ALPRE.PA Predilife

Healthcare Biotechnology Euronext Paris
0.8020 EUR
Close of Nov 8, 2026
0.7500 4.00
Market cap
EUR 3.16M
P/E
-
P/B
35.76x
ROE
-
Dividend yield
-
Fundamental score
1.5/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALPRE.PA undervalued?

Graham number

The Graham number of Predilife cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Predilife fundamental analysis

3 of 11 checks passed

ROE 2/2

ROE surpassing expectations (104.8%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

ROA 0/2

The stock's ROA (-74.9%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 2/2

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

DER 2/2

The stock has a low debt to equity ratio (-140%), which means it has a small amount of debt compared to the ownership it holds

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 0/1

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Predilife stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Predilife

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.

Full company profile